Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist.

Kitbunnadaj R, Zuiderveld OP, Christophe B, Hulscher S, Menge WM, Gelens E, Snip E, Bakker RA, Celanire S, Gillard M, Talaga P, Timmerman H, Leurs R.

J Med Chem. 2004 May 6;47(10):2414-7.

PMID:
15115383
2.
3.

N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist.

Kitbunnadaj R, Hashimoto T, Poli E, Zuiderveld OP, Menozzi A, Hidaka R, de Esch IJ, Bakker RA, Menge WM, Yamatodani A, Coruzzi G, Timmerman H, Leurs R.

J Med Chem. 2005 Mar 24;48(6):2100-7.

PMID:
15771452
4.

Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.

Kitbunnadaj R, Zuiderveld OP, De Esch IJ, Vollinga RC, Bakker R, Lutz M, Spek AL, Cavoy E, Deltent MF, Menge WM, Timmerman H, Leurs R.

J Med Chem. 2003 Dec 4;46(25):5445-57.

PMID:
14640553
5.

Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.

Ishikawa M, Watanabe T, Kudo T, Yokoyama F, Yamauchi M, Kato K, Kakui N, Sato Y.

J Med Chem. 2010 Sep 9;53(17):6445-56. doi: 10.1021/jm100643t.

PMID:
20690643
6.

A new potent and selective histamine H3 receptor agonist, 4-(1H-imidazol-4-ylmethyl)piperidine.

Vollinga RC, de Koning JP, Jansen FP, Leurs R, Menge WM, Timmerman H.

J Med Chem. 1994 Feb 4;37(3):332-3. No abstract available.

PMID:
8308858
7.
8.

4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.

Meier G, Krause M, Hüls A, Ligneau X, Pertz HH, Arrang JM, Ganellin CR, Schwartz JC, Schunack W, Stark H.

J Med Chem. 2004 May 6;47(10):2678-87.

PMID:
15115409
9.

Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.

Elz S, Kramer K, Pertz HH, Detert H, ter Laak AM, Kühne R, Schunack W.

J Med Chem. 2000 Mar 23;43(6):1071-84.

PMID:
10737740
10.

A selective human H(4)-receptor agonist: (-)-2-cyano-1-methyl-3-[(2R,5R)-5- [1H-imidazol-4(5)-yl]tetrahydrofuran-2-y] methylguanidine.

Hashimoto T, Harusawa S, Araki L, Zuiderveld OP, Smit MJ, Imazu T, Takashima S, Yamamoto Y, Sakamoto Y, Kurihara T, Leurs R, Bakker RA, Yamatodani A.

J Med Chem. 2003 Jul 3;46(14):3162-5.

PMID:
12825954
11.

Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.

Hey JA, Aslanian R, Bolser DC, Chapman RW, Egan RW, Rizzo CA, Shih NY, Fernandez X, McLeod RL, West R, Kreutner W.

Arzneimittelforschung. 1998 Sep;48(9):881-8.

PMID:
9793613
12.

New high affinity H3 receptor agonists without a basic side chain.

Kitbunnadaj R, Hoffmann M, Fratantoni SA, Bongers G, Bakker RA, Wieland K, el Jilali A, De Esch IJ, Menge WM, Timmerman H, Leurs R.

Bioorg Med Chem. 2005 Dec 1;13(23):6309-23. Epub 2005 Oct 5.

PMID:
16213736
13.

Novel partial agonists for the histamine H(3) receptor with high in vitro and in vivo activity.

Sasse A, Stark H, Reidemeister S, Hüls A, Elz S, Ligneau X, Ganellin CR, Schwartz JC, Schunack W.

J Med Chem. 1999 Oct 7;42(20):4269-74.

PMID:
10514298
14.

4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists.

Wijtmans M, Celanire S, Snip E, Gillard MR, Gelens E, Collart PP, Venhuis BJ, Christophe B, Hulscher S, van der Goot H, Lebon F, Timmerman H, Bakker RA, Lallemand BI, Leurs R, Talaga PE, de Esch IJ.

J Med Chem. 2008 May 22;51(10):2944-53. doi: 10.1021/jm7014149. Epub 2008 Apr 24.

PMID:
18433114
15.
16.

Novel histamine H(3)-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds.

Stark H, Sadek B, Krause M, Hüls A, Ligneau X, Ganellin CR, Arrang JM, Schwartz JC, Schunack W.

J Med Chem. 2000 Oct 19;43(21):3987-94.

PMID:
11052804
17.

Influence of bulky substituents on histamine h(3) receptor agonist/antagonist properties.

Sasse A, Ligneau X, Rouleau A, Elz S, Ganellin CR, Arrang JM, Schwartz JC, Schunack W, Stark H.

J Med Chem. 2002 Aug 29;45(18):4000-10.

PMID:
12190321
18.

Characterization of the binding site of the histamine H3 receptor. 1. Various approaches to the synthesis of 2-(1H-imidazol-4-yl)cyclopropylamine and histaminergic activity of (1R,2R)- and (1S,2S)-2-(1H-imidazol-4-yl)-cyclopropylamine.

De Esch IJ, Vollinga RC, Goubitz K, Schenk H, Appelberg U, Hacksell U, Lemstra S, Zuiderveld OP, Hoffmann M, Leurs R, Menge WM, Timmerman H.

J Med Chem. 1999 Apr 8;42(7):1115-22.

PMID:
10197956
19.

Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.

Kovalainen JT, Christiaans JA, Kotisaari S, Laitinen JT, Männistö PT, Tuomisto L, Gynther J.

J Med Chem. 1999 Apr 8;42(7):1193-202.

PMID:
10197963
20.

Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).

McLeod RL, Rizzo CA, West RE Jr, Aslanian R, McCormick K, Bryant M, Hsieh Y, Korfmacher W, Mingo GG, Varty L, Williams SM, Shih NY, Egan RW, Hey JA.

J Pharmacol Exp Ther. 2003 Jun;305(3):1037-44. Epub 2003 Mar 20.

Items per page

Supplemental Content

Write to the Help Desk